Triazole antifungal agents are the mainstay of
aspergillosis treatment. As highlighted in numerous studies, the global increase in the prevalence of
triazole resistance could hamper the management of
aspergillosis. In the present three-year study, 513 samples (213 clinical and 300 environmental samples) from 10 provinces of Iran were processed and screened in terms of
azole resistance (4 and 1 mg l-1 of
itraconazole and
voriconazole, respectively), using selective plates. Overall, 150 A. fumigatus isolates (71 clinical and 79 environmental isolates) were detected. The isolates were confirmed by partial sequencing of the β-
tubulin gene. Afterwards, in vitro antifungal susceptibility tests against
triazole agents were performed, based on the Clinical and Laboratory Standards Institute (CLSI) M38-A2 document. The CYP51A gene was sequenced in order to detect mutations. The MIC of
itraconazole against 10 (6.6 %) strains, including clinical (n=3, 4.2 %) and environmental (n=7, 8.8 %) strains, was higher than the breakpoint and epidemiological cut-off value. Based on the findings, the prevalence of
azole-resistant A. fumigatus in Iran has increased remarkablyfrom 3.3 % to 6.6 % in comparison with earlier epidemiological research. Among resistant isolates, TR34/L98H mutations in the CYP51A gene were the most prevalent (n=8, 80 %), whereas other point mutations (F46Y, G54W, Y121F, G138C, M172V, F219C, M220I, D255E, T289F, G432C and G448S mutations) were not detected. Although the number of patients affected by
azole-resistant A. fumigatus isolates was limited, strict supervision of clinical
azole-resistant A. fumigatus isolates and persistent environmental screening of
azole resistance are vital to the development of approaches for the management of
azole resistance in human pathogenic fungi.